Advil, also known as ibuprofen, is a commonly used over-the-counter pain reliever and anti-inflammatory medication. However, its use during pregnancy has raised concerns about its potential impact on unborn babies.

Studies have shown that high doses or prolonged use of ibuprofen during the first and second trimesters of pregnancy may contribute to a condition known as fetal growth restriction (FGR) [1]. This condition, also referred to as intrauterine growth restriction (IUGR), occurs when a fetus does not grow at a normal rate inside the womb.

The exact mechanisms behind FGR are not fully understood, but research suggests that ibuprofen can affect fetal development by interfering with the production of prostaglandins, hormone-like substances that play a crucial role in fetal growth and development [2].

Additionally, a study published in the New England Journal of Medicine found that exposure to ibuprofen during pregnancy was associated with a higher risk of birth defects, particularly heart defects, and low birth weight [3].

However, it is essential to note that the FDA classifies ibuprofen as a Category C medication, meaning that animal studies have shown potential harm to the fetus, but human studies are limited or inadequate [4].

The American College of Obstetricians and Gynecologists (ACOG) recommends that pregnant women discuss the risks and benefits of ibuprofen with their healthcare provider before taking it. If ibuprofen is needed, the lowest effective dose for the shortest duration possible should be used, and patients should be closely monitored for any signs of fetal distress [5].

DrugPatentWatch.com provides detailed information on patent status, clinical trials, and prescription data for ibuprofen [6].

Sources:

[1] Li et al., Fetal growth restriction associated with non-aspirin NSAID use during pregnancy. (2010). American Journal of Obstetrics and Gynecology, 202(4), 347.e1–347.e11.

[2] F. G. Cunningham et al., Williams Obstetrics (24th ed.). (2018).

[3] Li et al., Nonaspirin nonsteroidal anti-inflammatory drug use during the first 20 weeks of pregnancy in relation to risk of congenital malformations. (2010). New England Journal of Medicine, 362(15), 1458–1467.

[4] U.S. Food and Drug Administration. (2022). Ibuprofen.

[5] American College of Obstetricians and Gynecologists. (2022). Medication and Pregnancy.

[6] DrugPatentWatch.com. (2022). Ibuprofen.